Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its exact mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle, leading to vasodilation. It may also have some beta-adrenergic agonist activity.
## Primary Indications
* Treatment of peripheral vascular disease (e.g., arteriosclerosis obliterans, Raynaud's disease) to improve blood flow.
## Adult Dosing
* **Usual dose:** 10 mg to 20 mg orally every 3 to 4 times daily.
* **Maximum dose:** Not clearly defined, but doses above 20 mg are generally not recommended due to increased adverse effects without significant added benefit.
## Pediatric Dosing
* Data for pediatric use is limited. Dosing should be individualized by a pediatrician based on patient weight and clinical response.
## Dose Adjustments
* No specific dose adjustments are typically required for hepatic or renal impairment, as isoxsuprine is metabolized in the liver and excreted by the kidneys. However, caution may be warranted in patients with severe organ dysfunction.
## Contraindications
* Hypersensitivity to isoxsuprine.
* Should not be administered in patients where vasodilation may be dangerous (e.g., patients with severe hypotension, tachycardia, or congestive heart failure).
## Adverse Effects
* **Common:** Flushing, dizziness, nausea, vomiting, abdominal distress, rash, weakness, nervousness, drowsiness.
* **Less Common:** Hypotension, tachycardia, paradoxical increase in angina.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive medications, leading to hypotension.
* **Sympathomimetic agents:** Concurrent use may lead to additive cardiovascular effects (e.g., increased heart rate, blood pressure).
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease improvement.
* Signs of adverse effects, particularly hypotension and cardiac effects.
## Clinical Pearls
* Isoxsuprine is generally not considered a first-line agent for peripheral vascular disease due to limited evidence of significant clinical benefit compared to other therapies.
* Effectiveness can vary significantly between individuals.
* Administer with meals to minimize gastrointestinal upset.
* Discontinue if adverse effects occur or if no clinical improvement is observed after a reasonable trial period.
***
**Disclaimer:** This information is intended for clinical professionals and does not replace a thorough review of the most current prescribing information, clinical guidelines, or patient-specific factors. Always verify current drug information before making clinical decisions.
